Tools
Chikungunya Fever
Introduction
Chikungunya virus (CHIKV) is an arthropod-borne alphavirus belonging to the family Togaviridae, primarily transmitted by Aedes mosquitoes. CHIKV causes an acute febrile illness characterized by high fever, rash, and severe polyarthralgia, commonly known as chikungunya fever, which can progress to chronic, debilitating arthritic symptoms lasting months to years.[1][2] Originally isolated from the Makonde Plateau in Tanzania in 1952, the virus's name derives from a Makonde phrase meaning "that which bends up," describing the stooped posture of afflicted patients.[2] Historically restricted to Africa and Asia, CHIKV’s global presence expanded significantly following the massive outbreak in Reunion Island in 2005 and 2006, which affected approximately 35% of the population.[3] Since 2013, the virus has spread across the Americas via the Caribbean island of St. Martin, resulting in widespread transmission in tropical and subtropical regions worldwide, posing a significant public health concern.[4][5][6]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Both Aedes aegypti and Aedes albopictus (Asian tiger mosquito) mosquitoes transmit CHIKV and exhibit high vector competence and capacity, facilitating viral spread.[7][8] Vector competence refers to the mosquito’s biological ability to ingest the virus and support its replication and transmission. In contrast, vectorial capacity encompasses factors, eg, mosquito density, survival, feeding behavior, and the extrinsic incubation period.[9] Ae aegypti has been present in the United States for over 300 years, whereas experts report the first appearance of Ae albopictus in 1985.
A key adaptation occurred during the 2005 to 2006 Indian Ocean outbreak, when CHIKV acquired a mutation in the E1 envelope protein, enhancing its fitness for Ae albopictus and increasing its transmissibility. This mutation expanded CHIKV's geographic range by enabling infection via a more widely distributed mosquito vector.[8] Human travel and trade have further contributed to the spread of infected mosquitoes and the virus, complicating control efforts.[10]
Epidemiology
After its discovery in Tanzania, CHIKV maintained an endemic sylvatic cycle in Africa before causing major outbreaks in Asia and the Indian Ocean region.[11] The first confirmed introduction into the Americas was reported in the Caribbean in 2013, with local transmission in Florida detected in 2014.[3][4] The virus rapidly spread across the Caribbean islands and Central and South America, facilitated by infected travelers and the widespread presence of competent Aedes vectors.[5]
Mosquito eggs and larvae have also been transported by shipping and air traffic to new regions, contributing to the establishment of invasive vector populations.[2] While transmission is predominantly mosquito-borne, vertical maternal-fetal transmission and transmission through blood products have been documented, especially during outbreaks, eg, the Reunion Island epidemic.[12][13] Coinfection with other arboviruses transmitted by Ae aegypti and Ae albopictus, eg, Dengue (DENV) and Zika (ZIKV) viruses, presents diagnostic and therapeutic challenges due to overlapping clinical presentations and geographic distributions.[14]
Pathophysiology
CHIKV transmission occurs via 2 cycles: an urban cycle involving human-mosquito-human transmission, predominant in the Americas, and a sylvatic cycle involving non-human primates and mosquitoes in Africa. The aforementioned mutation in the E1 protein enhances viral fitness in Ae albopictus, facilitating the expansion of the urban cycle.[6][15] After inoculation via a mosquito bite, CHIKV infects human epithelial and endothelial cells, fibroblasts, and monocyte-derived macrophages.[16][17]
The virus disseminates through the lymphatic system and bloodstream, resulting in high-level viremia and seeding of target organs, including muscles, joints, liver, and the central nervous system.[16][18] The acute symptoms are mediated by robust inflammatory responses, initially involving CD8+ T cells, later CD4+ T cells, and proinflammatory cytokines.[19] Persistent infection of monocyte-derived macrophages in joint tissues is hypothesized to underlie chronic arthritis and polyarthralgia.[9][19]
Histopathology
CHIKV is a positive-sense, single-stranded RNA alphavirus comprising 3 genotypes: Asian, West African, and East-Central-South African.[20] The virus is thermolabile, sensitive to temperatures above 58 °C, which limits its environmental persistence outside the vector and host.[6] Histopathological studies of affected joint tissues show chronic synovitis characterized by macrophage infiltration and inflammatory cytokine expression, correlating with clinical joint pain and swelling.[9]
History and Physical
After a 3- to 7-day incubation period, patients typically develop sudden high-grade fever, severe bilateral symmetrical polyarthralgia, and myalgia.[1][11][21] Joint involvement preferentially affects distal joints, especially the hands, wrists, ankles, and knees, and is often accompanied by intense pain lasting 1 to 3 weeks. However, symptoms may persist longer.[21][22] A generalized maculopapular rash typically appears approximately 3 days after fever onset, initially involving the extremities and sometimes spreading to the trunk.[23] Less commonly, vesiculobullous and mucocutaneous lesions are reported.[23][24]
Other systemic symptoms include headache, abdominal pain, diarrhea, vomiting, and generalized lymphadenopathy. Although not primarily neurotropic, patients with a CHIKV infection may experience neurologic complications, notably neonatal encephalitis from vertical transmission.[3][25] Ocular manifestations, eg, conjunctivitis, anterior uveitis, iridocyclitis, and retinitis, are possible, and patients in endemic regions may experience recurrent ocular inflammation.[26][27][28][29]
Evaluation
The diagnosis of CHIKV infection is primarily clinical in endemic areas or following travel to affected regions, with fever and polyarthralgia having a sensitivity of 84%, a positive predictive value (PPV) of 71%, and a negative predictive value (NPV) of 83%.[30] However, coexisting circulation with DENV and ZIKV complicates clinical diagnosis due to overlapping symptoms.[31] Laboratory confirmation relies on detection of viral RNA via reverse transcription polymerase chain reaction (RT-PCR) during the acute phase (first 5 days of illness) or serologic detection of virus-specific IgM and IgG antibodies using ELISA or indirect immunofluorescence assays thereafter.[32][33][34] The CDC recommends simultaneous testing for CHIKV, DENV, and ZIKV in suspected cases to identify coinfections.[35] Lymphopenia and thrombocytopenia may be seen on laboratory evaluation.
Treatment / Management
Currently, no widely available antiviral therapy exists for CHIKV infection, and management remains primarily supportive.[17][36] Treatment focuses on adequate hydration, rest, and pain control, typically with acetaminophen. Clinicians should avoid NSAIDs and aspirin until they exclude DENV infection due to the risk of hemorrhagic complications.[36] Please see StatPearls' companion topic, "Dengue Fever," for an in-depth discussion of the presentation, evaluation, and treatment of dengue fever. In the post-acute and chronic phases, corticosteroids and disease-modifying antirheumatic drugs (DMARDs), eg, hydroxychloroquine, may be used to manage persistent inflammatory arthritis. Ocular complications have been treated successfully with topical corticosteroids and cycloplegics.[37] Experimental therapies, including siRNA-based antivirals, are under investigation but are not yet in routine clinical use.[38][39][40](B3)
Preventive strategies focus on vector control and personal protection, including the use of insect repellents (eg, DEET), protective clothing, bed nets, and the elimination of mosquito breeding sites.[41][42] Clinicians and public health teams commonly use insecticides (eg, pyrethroids and organophosphates), although increasing resistance remains a growing concern.[43] Currently, 2 chikungunya vaccines have been developed. The recombinant chikungunya virus vaccine, or virus-like particle (VLP) vaccine, is approved by both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for patients aged 12 years and older.
The live-attenuated chikungunya virus vaccine is only approved by the EMA, as the FDA withdrew approval due to the risk of adverse events. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for people traveling to areas with chikungunya outbreaks or planning travel of 6 months or longer to a country with elevated risk.[44][45] Additional candidates for vaccination are laboratory workers at risk of exposure to the chikungunya virus.(A1)
Differential Diagnosis
Given the nonspecific presentation of fever, arthralgia, and rash, the differential diagnosis for both acute and chronic manifestations of chikungunya fever is broad. DENV and ZIKV share similar clinical features and are transmitted by the same Aedes mosquito, often prompting evaluation for all 3 infections based on clinical context and local epidemiology.[35] Other infectious causes to consider include the following:
- Malaria
- Yellow fever
- Leptospirosis
- Measles
- Mononucleosis
- African tick bite fever
- Ross River virus
- Oropouche virus
Chronic chikungunya-associated arthralgia can mimic more common rheumatologic conditions and may be difficult to distinguish clinically. Additionally, patients with preexisting joint disease who develop CHIKV infection may experience more severe symptoms and increased morbidity.[46] The differential diagnosis for chronic manifestations includes the following:
- Seronegative rheumatoid arthritis
- Rheumatoid arthritis
- Hepatitis C
- Systemic lupus erythematosus
- Reactive arthritis
Prognosis
While CHIKV infection has a low case fatality ratio, this virus is associated with substantial morbidity due to chronic polyarthralgia and arthritis persisting beyond 6 weeks postinfection.[47][48] Studies from Aruba and French Guiana have reported chronic rheumatic symptoms in 26% to 40% of confirmed cases, respectively, at 3 to 6 months.[46][49] Older age and preexisting joint disease increase the risk of severe chronic manifestations.[50][51]
Complications
The most common chronic manifestation of CHIKV infection is persistent inflammatory arthritis characterized by recurrent or prolonged joint pain and swelling, which may last for months to years and, in some cases, require rheumatologic evaluation and treatment. Patients with preexisting joint disease may experience more severe symptoms and increased morbidity. Ocular complications include conjunctivitis, iridocyclitis, episcleritis, optic neuritis, and retinitis. These manifestations are often self-limited but can occasionally result in vision impairment and may require targeted therapy.[28][29]
Additionally, neurologic complications are less common but can be severe, particularly in vulnerable populations, eg, older adults and immunocompromised individuals. Reported complications include encephalitis and Guillain-Barré syndrome.[25] Although most patients recover fully, these complications highlight the potential for significant long-term morbidity and underscore the importance of early recognition and appropriate management.[50][52]
Consultations
Due to the complex and chronic nature of post-CHIKV arthritis, rheumatology consultation is often necessary for management of persistent joint symptoms. Patients presenting with ocular signs or symptoms should undergo ophthalmology evaluation to prevent long-term sequelae.[50]
Deterrence and Patient Education
Effective mosquito avoidance and vector control are the best preventive measures for CHIKV infection, as no widely accessible curative therapy exists and treatment is primarily supportive. Healthcare professionals play a critical role in educating patients, especially travelers, pregnant individuals, older adults, and those with comorbidities, about risk-reduction strategies. Clinicians should advise patients to use EPA-registered insect repellents (eg, DEET), wear long-sleeved clothing, and use permethrin-treated garments when appropriate. Furthermore, because Aedes mosquitoes bite during the day, clinicians should emphasize protection during daylight hours as well as at dawn and dusk. Additional measures include staying in air-conditioned or well-screened environments, using bed nets when necessary, and eliminating standing water around homes to reduce breeding sites.
Clinicians should counsel patients with suspected or confirmed CHIKV infection to continue mosquito precautions during the first week of illness to prevent further transmission. Education should also include guidance on symptom management, hydration, and appropriate medication use, including avoidance of NSAIDs until after excluding dengue as a potential cause of the patient's symptoms. For patients with persistent joint symptoms, clinicians should set expectations for a prolonged recovery and discuss follow-up care. Clear communication, culturally appropriate education, and coordination with public health resources are essential to reducing transmission risk and improving patient outcomes.
Pearls and Other Issues
The following factors should be kept in mind when managing CHIKV:
- CHIKV is an arthropod-borne alphavirus transmitted primarily by Ae aegypti and Ae albopictus mosquitoes, prevalent in tropical and subtropical climates.[1][8]
- Two vaccines are available, but only to those at significant risk of acquiring the disease, as the live-virus vaccine has notable adverse effects and has been withdrawn in the United States. Those living and working in high-risk areas for more than 6 months of the year, and other select groups, eg, researchers, can consider the risks and benefits of vaccination with the live-virus vaccine. The recombinant vaccine is approved by both the FDA and EMA for those older than 12 years with risk factors for acquiring the disease.[44][45]
- Coinfection with DENV and ZIKV viruses complicates diagnosis and management due to overlapping symptoms and shared vectors.[14][35]
- Acute symptoms include high fever, polyarthralgia, rash, myalgia, and headache, while chronic arthritis is the most disabling complication.[1][21][47]
- Diagnosis relies on clinical suspicion confirmed by RT-PCR in early disease or serology later; simultaneous testing for other arboviruses is recommended.[32][35]
- Supportive care remains the cornerstone of treatment; no specific antivirals are currently approved.[36][53][54]
- Prevention through vector control and personal protective measures is paramount to limit disease spread.[41][42]
- Chikungunya fever is nationally notifiable to the CDC and monitored closely by global health agencies.[6][18]
Enhancing Healthcare Team Outcomes
Chikungunya fever is a mosquito-borne viral illness caused by the CHIKV and transmitted primarily by Aedes mosquitoes. It typically presents with an acute febrile illness characterized by severe polyarthralgia, rash, and fatigue, with joint symptoms that may persist for months to years in some patients. Although mortality is low, the disease can cause significant morbidity, particularly in older adults and those with underlying medical conditions. Diagnosis is based on clinical presentation and confirmed with molecular or serologic testing, while management remains largely supportive, focusing on symptom control and prevention of complications.
Effective management of chikungunya fever requires coordinated interprofessional care to optimize patient outcomes and safety. Physicians and advanced practitioners play a central role in diagnosis, risk stratification, and management planning, including distinguishing CHIKV infection from other arboviral illnesses. Nurses contribute through patient monitoring, symptom management, and education on hydration, medication use, and vector prevention strategies. Pharmacists support safe and appropriate medication selection, particularly in avoiding NSAIDs until dengue has been excluded, and assisting with the management of chronic arthralgia. Collaboration with specialists in rheumatology and ophthalmology may be necessary for patients with persistent or complicated disease. Clear communication among team members and with public health authorities enhances surveillance, outbreak response, and patient education, ultimately improving patient-centered care, reducing complications, and strengthening overall healthcare team performance.
References
Horwood PF, Buchy P. Chikungunya. Revue scientifique et technique (International Office of Epizootics). 2015 Aug:34(2):479-89 [PubMed PMID: 26601450]
Paupy C, Delatte H, Bagny L, Corbel V, Fontenille D. Aedes albopictus, an arbovirus vector: from the darkness to the light. Microbes and infection. 2009 Dec:11(14-15):1177-85. doi: 10.1016/j.micinf.2009.05.005. Epub 2009 May 18 [PubMed PMID: 19450706]
Level 3 (low-level) evidenceWeaver SC, Forrester NL. Chikungunya: Evolutionary history and recent epidemic spread. Antiviral research. 2015 Aug:120():32-9. doi: 10.1016/j.antiviral.2015.04.016. Epub 2015 May 12 [PubMed PMID: 25979669]
Rougeron V, Sam IC, Caron M, Nkoghe D, Leroy E, Roques P. Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015 Mar:64():144-52. doi: 10.1016/j.jcv.2014.08.032. Epub 2014 Oct 22 [PubMed PMID: 25453326]
Level 3 (low-level) evidencePialoux G, Gaüzère BA, Jauréguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. The Lancet. Infectious diseases. 2007 May:7(5):319-27 [PubMed PMID: 17448935]
Level 3 (low-level) evidenceGanesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017 Dec 1:9(12):. doi: 10.3390/v9120368. Epub 2017 Dec 1 [PubMed PMID: 29194359]
Fernández-Salas I, Danis-Lozano R, Casas-Martínez M, Ulloa A, Bond JG, Marina CF, Lopez-Ordóñez T, Elizondo-Quiroga A, Torres-Monzón JA, Díaz-González EE. Historical inability to control Aedes aegypti as a main contributor of fast dispersal of chikungunya outbreaks in Latin America. Antiviral research. 2015 Dec:124():30-42. doi: 10.1016/j.antiviral.2015.10.015. Epub 2015 Oct 27 [PubMed PMID: 26518229]
Higgs S, Vanlandingham D. Chikungunya virus and its mosquito vectors. Vector borne and zoonotic diseases (Larchmont, N.Y.). 2015 Apr:15(4):231-40. doi: 10.1089/vbz.2014.1745. Epub 2015 Feb 12 [PubMed PMID: 25674945]
Level 3 (low-level) evidenceKramer LD, Ciota AT. Dissecting vectorial capacity for mosquito-borne viruses. Current opinion in virology. 2015 Dec:15():112-8. doi: 10.1016/j.coviro.2015.10.003. Epub 2015 Dec 6 [PubMed PMID: 26569343]
Level 3 (low-level) evidenceLounibos LP, Kramer LD. Invasiveness of Aedes aegypti and Aedes albopictus and Vectorial Capacity for Chikungunya Virus. The Journal of infectious diseases. 2016 Dec 15:214(suppl 5):S453-S458 [PubMed PMID: 27920173]
de Lima Cavalcanti TYV, Pereira MR, de Paula SO, Franca RFO. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. Viruses. 2022 May 5:14(5):. doi: 10.3390/v14050969. Epub 2022 May 5 [PubMed PMID: 35632709]
Renault P, Balleydier E, D'Ortenzio E, Bâville M, Filleul L. Epidemiology of Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Medecine et maladies infectieuses. 2012 Mar:42(3):93-101. doi: 10.1016/j.medmal.2011.12.002. Epub 2012 Jan 26 [PubMed PMID: 22280563]
Level 3 (low-level) evidenceContopoulos-Ioannidis D, Newman-Lindsay S, Chow C, LaBeaud AD. Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis. PLoS neglected tropical diseases. 2018 Jun:12(6):e0006510. doi: 10.1371/journal.pntd.0006510. Epub 2018 Jun 13 [PubMed PMID: 29897898]
Level 1 (high-level) evidenceSingh J, Dinkar A, Singh RG, Siddiqui MS, Sinha N, Singh SK. Clinical profile of dengue fever and coinfection with chikungunya. Tzu chi medical journal. 2018 Jul-Sep:30(3):158-164. doi: 10.4103/tcmj.tcmj_138_17. Epub [PubMed PMID: 30069124]
Lum FM, Ng LF. Cellular and molecular mechanisms of chikungunya pathogenesis. Antiviral research. 2015 Aug:120():165-74. doi: 10.1016/j.antiviral.2015.06.009. Epub 2015 Jun 16 [PubMed PMID: 26092642]
Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O. Characterization of reemerging chikungunya virus. PLoS pathogens. 2007 Jun:3(6):e89 [PubMed PMID: 17604450]
Sun W, Shi S, Liao S, Zhai M. Chikungunya fever: pathogenesis and mechanisms underlying pain symptoms. Frontiers in immunology. 2025:16():1679385. doi: 10.3389/fimmu.2025.1679385. Epub 2025 Nov 11 [PubMed PMID: 41306980]
Kam YW, Ong EK, Rénia L, Tong JC, Ng LF. Immuno-biology of Chikungunya and implications for disease intervention. Microbes and infection. 2009 Dec:11(14-15):1186-96. doi: 10.1016/j.micinf.2009.09.003. Epub 2009 Sep 6 [PubMed PMID: 19737625]
Level 3 (low-level) evidenceChow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, Barkham T, Yang H, Rénia L, Leo YS, Ng LF. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. The Journal of infectious diseases. 2011 Jan 15:203(2):149-57. doi: 10.1093/infdis/jiq042. Epub [PubMed PMID: 21288813]
Level 2 (mid-level) evidenceCaglioti C, Lalle E, Castilletti C, Carletti F, Capobianchi MR, Bordi L. Chikungunya virus infection: an overview. The new microbiologica. 2013 Jul:36(3):211-27 [PubMed PMID: 23912863]
Level 3 (low-level) evidenceHua C, Combe B. Chikungunya Virus-Associated Disease. Current rheumatology reports. 2017 Oct 5:19(11):69. doi: 10.1007/s11926-017-0694-0. Epub 2017 Oct 5 [PubMed PMID: 28983760]
Madariaga M, Ticona E, Resurrecion C. Chikungunya: bending over the Americas and the rest of the world. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2016 Jan-Feb:20(1):91-8. doi: 10.1016/j.bjid.2015.10.004. Epub 2015 Dec 17 [PubMed PMID: 26707971]
Pakran J, George M, Riyaz N, Arakkal R, George S, Rajan U, Khader A, Thomas S, Abdurahman R, Sasidharanpillai S, Thumbayil L. Purpuric macules with vesiculobullous lesions: a novel manifestation of Chikungunya. International journal of dermatology. 2011 Jan:50(1):61-9. doi: 10.1111/j.1365-4632.2010.04644.x. Epub [PubMed PMID: 21182504]
Bandyopadhyay D, Ghosh SK. Mucocutaneous features of Chikungunya fever: a study from an outbreak in West Bengal, India. International journal of dermatology. 2008 Nov:47(11):1148-52. doi: 10.1111/j.1365-4632.2008.03817.x. Epub [PubMed PMID: 18986446]
Arpino C, Curatolo P, Rezza G. Chikungunya and the nervous system: what we do and do not know. Reviews in medical virology. 2009 May:19(3):121-9. doi: 10.1002/rmv.606. Epub [PubMed PMID: 19274635]
Level 3 (low-level) evidenceUlloa-Padilla JP, Dávila PJ, Izquierdo NJ, García-Rodríguez O, Jiménez IZ. Ocular Symptoms and Signs of Chikungunya Fever in Puerto Rico. Puerto Rico health sciences journal. 2018 Jun:37(2):83-87 [PubMed PMID: 29905918]
Salceanu SO, Raman V. Recurrent chikungunya retinitis. BMJ case reports. 2018 Aug 27:2018():. pii: bcr-2017-222864. doi: 10.1136/bcr-2017-222864. Epub 2018 Aug 27 [PubMed PMID: 30150331]
Level 3 (low-level) evidenceMartínez-Pulgarín DF, Chowdhury FR, Villamil-Gomez WE, Rodriguez-Morales AJ, Blohm GM, Paniz-Mondolfi AE. Ophthalmologic aspects of chikungunya infection. Travel medicine and infectious disease. 2016 Sep-Oct:14(5):451-457. doi: 10.1016/j.tmaid.2016.05.008. Epub 2016 May 26 [PubMed PMID: 27238905]
Mahendradas P, Ranganna SK, Shetty R, Balu R, Narayana KM, Babu RB, Shetty BK. Ocular manifestations associated with chikungunya. Ophthalmology. 2008 Feb:115(2):287-91 [PubMed PMID: 17631967]
Level 2 (mid-level) evidenceThiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral research. 2013 Sep:99(3):345-70. doi: 10.1016/j.antiviral.2013.06.009. Epub 2013 Jun 28 [PubMed PMID: 23811281]
Level 3 (low-level) evidenceLe Coupanec A, Tchankouo-Nguetcheu S, Roux P, Khun H, Huerre M, Morales-Vargas R, Enguehard M, Lavillette D, Missé D, Choumet V. Co-Infection of Mosquitoes with Chikungunya and Dengue Viruses Reveals Modulation of the Replication of Both Viruses in Midguts and Salivary Glands of Aedes aegypti Mosquitoes. International journal of molecular sciences. 2017 Aug 4:18(8):. doi: 10.3390/ijms18081708. Epub 2017 Aug 4 [PubMed PMID: 28777313]
Jain J, Nayak K, Tanwar N, Gaind R, Gupta B, Shastri JS, Bhatnagar RK, Kaja MK, Chandele A, Sunil S. Clinical, Serological, and Virological Analysis of 572 Chikungunya Patients From 2010 to 2013 in India. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Jul 1:65(1):133-140. doi: 10.1093/cid/cix283. Epub [PubMed PMID: 28379375]
Panning M, Grywna K, van Esbroeck M, Emmerich P, Drosten C. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerging infectious diseases. 2008 Mar:14(3):416-22. doi: 10.3201/eid1403.070906. Epub [PubMed PMID: 18325256]
Level 2 (mid-level) evidenceKumar P, Pok KY, Tan LK, Angela C, Leo YS, Ng LC. Development and evaluation of baculovirus-expressed Chikungunya virus E1 envelope proteins for serodiagnosis of Chikungunya infection. Journal of virological methods. 2014 Sep:206():67-75. doi: 10.1016/j.jviromet.2014.05.014. Epub 2014 May 29 [PubMed PMID: 24880071]
Loconsole D, Metallo A, De Robertis AL, Morea A, Quarto M, Chironna M. Seroprevalence of Dengue Virus, West Nile Virus, Chikungunya Virus, and Zika Virus in International Travelers Attending a Travel and Migration Center in 2015-2017, Southern Italy. Vector borne and zoonotic diseases (Larchmont, N.Y.). 2018 Jun:18(6):331-334. doi: 10.1089/vbz.2017.2260. Epub 2018 Apr 23 [PubMed PMID: 29683399]
Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, Leparc-Goffart I, Hoen B, Gandjbakhch F, Rene-Corail P, Franco JM, Caumes E, Combe B, Poiraudeau S, Gane-Troplent F, Djossou F, Schaerverbeke T, Criquet-Hayot A, Carrere P, Malvy D, Gaillard P, Wendling D, Société de pathologie infectieuse de langue francaise. French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Medecine et maladies infectieuses. 2015 Jul:45(7):243-63. doi: 10.1016/j.medmal.2015.05.007. Epub 2015 Jun 25 [PubMed PMID: 26119684]
Mahendradas P, Avadhani K, Shetty R. Chikungunya and the eye: a review. Journal of ophthalmic inflammation and infection. 2013 Feb 11:3(1):35. doi: 10.1186/1869-5760-3-35. Epub 2013 Feb 11 [PubMed PMID: 23514031]
Parashar D, Paingankar MS, Kumar S, Gokhale MD, Sudeep AB, Shinde SB, Arankalle VA. Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS neglected tropical diseases. 2013:7(9):e2405. doi: 10.1371/journal.pntd.0002405. Epub 2013 Sep 5 [PubMed PMID: 24040429]
Level 3 (low-level) evidenceSubudhi BB, Chattopadhyay S, Mishra P, Kumar A. Current Strategies for Inhibition of Chikungunya Infection. Viruses. 2018 May 3:10(5):. doi: 10.3390/v10050235. Epub 2018 May 3 [PubMed PMID: 29751486]
Oliveira AF, Teixeira RR, Oliveira AS, Souza AP, Silva ML, Paula SO. Potential Antivirals: Natural Products Targeting Replication Enzymes of Dengue and Chikungunya Viruses. Molecules (Basel, Switzerland). 2017 Mar 22:22(3):. doi: 10.3390/molecules22030505. Epub 2017 Mar 22 [PubMed PMID: 28327521]
Audain G, Maher C. Prevention and Control of Worldwide Mosquito-Borne Illnesses: Nurses as Teachers. Online journal of issues in nursing. 2017 Jan 31:22(1):5. doi: 10.3912/OJIN.Vol22No01Man05. Epub 2017 Jan 31 [PubMed PMID: 28488821]
Silva NMD, Teixeira RAG, Cardoso CG, Siqueira Junior JB, Coelho GE, Oliveira ESF. Chikungunya surveillance in Brazil: challenges in the context of Public Health. Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil. 2018 Sep 3:27(3):e2017127. doi: 10.5123/S1679-49742018000300003. Epub 2018 Sep 3 [PubMed PMID: 30183867]
Moyes CL, Vontas J, Martins AJ, Ng LC, Koou SY, Dusfour I, Raghavendra K, Pinto J, Corbel V, David JP, Weetman D. Contemporary status of insecticide resistance in the major Aedes vectors of arboviruses infecting humans. PLoS neglected tropical diseases. 2017 Jul:11(7):e0005625. doi: 10.1371/journal.pntd.0005625. Epub 2017 Jul 20 [PubMed PMID: 28727779]
Zhang Y, Wu J, Cheng X, Yang Y, Wang X, Zhao X, Wang X, Ouyang H, Ai J, Zhang W. Global resurgence of Chikungunya virus: outbreak drivers and emerging solutions. Emerging microbes & infections. 2026 Dec:15(1):2603714. doi: 10.1080/22221751.2025.2603714. Epub 2026 Jan 2 [PubMed PMID: 41392880]
Richardson JS, Anderson DM, Mendy J, Tindale LC, Muhammad S, Loreth T, Tredo SR, Warfield KL, Ramanathan R, Caso JT, Jenkins VA, Ajiboye P, Bedell L, EBSI-CV-317-004 Study Group. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2025 Apr 19:405(10487):1343-1352. doi: 10.1016/S0140-6736(25)00345-9. Epub 2025 Mar 27 [PubMed PMID: 40158526]
Level 1 (high-level) evidenceBonifay T, Lienne JF, Bagoée C, Santa F, Vesin G, Walter G, Nacher M, Vaserman N, Djossou F, Epelboin L. Prevalence and risk factors of post chikungunya rheumatic musculoskeletal disorders: a prospective follow-up study in French Guiana. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2018 Nov:37(11):2159-2164. doi: 10.1007/s10096-018-3353-0. Epub 2018 Aug 17 [PubMed PMID: 30120648]
Silva JVJ Jr, Ludwig-Begall LF, Oliveira-Filho EF, Oliveira RAS, Durães-Carvalho R, Lopes TRR, Silva DEA, Gil LHVG. A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control. Acta tropica. 2018 Dec:188():213-224. doi: 10.1016/j.actatropica.2018.09.003. Epub 2018 Sep 6 [PubMed PMID: 30195666]
Level 2 (mid-level) evidencede Souza WM, Fumagalli MJ, de Lima STS, Parise PL, Carvalho DCM, Hernandez C, de Jesus R, Delafiori J, Candido DS, Carregari VC, Muraro SP, Souza GF, Simões Mello LM, Claro IM, Díaz Y, Kato RB, Trentin LN, Costa CHS, Maximo ACBM, Cavalcante KF, Fiuza TS, Viana VAF, Melo MEL, Ferraz CPM, Silva DB, Duarte LMF, Barbosa PP, Amorim MR, Judice CC, Toledo-Teixeira DA, Ramundo MS, Aguilar PV, Araújo ELL, Costa FTM, Cerqueira-Silva T, Khouri R, Boaventura VS, Figueiredo LTM, Fang R, Moreno B, López-Vergès S, Mello LP, Skaf MS, Catharino RR, Granja F, Martins-de-Souza D, Plante JA, Plante KS, Sabino EC, Diamond MS, Eugenin E, Proença-Módena JL, Faria NR, Weaver SC. Pathophysiology of chikungunya virus infection associated with fatal outcomes. Cell host & microbe. 2024 Apr 10:32(4):606-622.e8. doi: 10.1016/j.chom.2024.02.011. Epub 2024 Mar 12 [PubMed PMID: 38479396]
Huits R, De Kort J, Van Den Berg R, Chong L, Tsoumanis A, Eggermont K, Bartholomeeusen K, Ariën KK, Jacobs J, Van Esbroeck M, Bottieau E, Cnops L. Chikungunya virus infection in Aruba: Diagnosis, clinical features and predictors of post-chikungunya chronic polyarthralgia. PloS one. 2018:13(4):e0196630. doi: 10.1371/journal.pone.0196630. Epub 2018 Apr 30 [PubMed PMID: 29709007]
Sharma SK, Jain S. Chikungunya: A rheumatologist's perspective. International journal of rheumatic diseases. 2018 Mar:21(3):584-601. doi: 10.1111/1756-185X.13273. Epub 2018 Feb 12 [PubMed PMID: 29431292]
Level 3 (low-level) evidenceBrito C, Falcão MB, de Albuquerque MFPM, Cerqueira-Silva T, Teixeira MG, Franca RFO. Chikungunya: From Hypothesis to Evidence of Increased Severe Disease and Fatalities. Viruses. 2025 Jan 3:17(1):. doi: 10.3390/v17010062. Epub 2025 Jan 3 [PubMed PMID: 39861851]
Runowska M, Majewski D, Niklas K, Puszczewicz M. Chikungunya virus: a rheumatologist's perspective. Clinical and experimental rheumatology. 2018 May-Jun:36(3):494-501 [PubMed PMID: 29533749]
Level 3 (low-level) evidenceSchwameis M, Buchtele N, Wadowski PP, Schoergenhofer C, Jilma B. Chikungunya vaccines in development. Human vaccines & immunotherapeutics. 2016 Mar 3:12(3):716-31. doi: 10.1080/21645515.2015.1101197. Epub [PubMed PMID: 26554522]
Cai L, Hu X, Liu S, Wang L, Lu H, Tu H, Huang X, Tong Y. The research progress of Chikungunya fever. Frontiers in public health. 2022:10():1095549. doi: 10.3389/fpubh.2022.1095549. Epub 2023 Jan 9 [PubMed PMID: 36699921]